The growing practice of exploiting noninvasive fluorescence-based techniques to study G protein-coupled receptor pharmacology at the single cell and single molecule level demands the availability of high-quality fluorescent ligands. To this end, this study evaluated a new series of red-emitting ligands for the human β-adrenoceptor family. Upon the basis of the orthosteric ligands propranolol, alprenolol, and pindolol, the synthesized linker-modified congeners were coupled to the commercially available fluorophore BODIPY 630/650-X. This yielded high-affinity βadrenoceptor fluorescent ligands for both the propranolol and alprenolol derivatives; however, the pindolol-based products displayed lower affinity. A fluorescent diethylene glycol linked propranolol derivative (18a) had the highest affinity (log K D of À9.53 and À8.46 as an antagonist of functional β2and β1-mediated responses, respectively). Imaging studies with this compound further confirmed that it can be employed to selectively label the human β2-adrenoceptor in single living cells, with receptor-associated binding prevented by preincubation with the nonfluorescent β2-selective antagonist 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol (ICI 118551) (J. Cardiovasc. Pharmacol. 1983, 5, 430À437.) dx.
' INTRODUCTION G-protein coupled receptors (GPCRs) remain a prime target for potential disease modulation, and therefore, research focused upon them persists as a significant component of the modern day drug discovery arena. 2 The β-adrenoceptors (β-AR) represent just one subset of this broad receptor family and are themselves further classified into three specific subtypes, β1-, β2-, and β3-AR. 3 For several decades these subtypes have been the molecular target for numerous drug discovery projects, and the drugs resulting from these endeavors have established themselves as key therapeutic agents in the treatment of numerous chronic cardiovascular and respiratory diseases. 4 More recently, their potential involvement in metastatic cancer progression has become apparent and rekindled further the therapeutic importance of this receptor class. 5, 6 Our current understanding of the molecular pharmacology of the β-AR has been derived primarily from the use of radioligand binding techniques for the elucidation of ligandÀreceptor interactions and the quantification of intracellular second messenger generation. As such, this type of experiment requires the use of large numbers of cells, and the data generated represents an average for the entire cell population. Fluorescent techniques, however, offer a wider spectrum of more detailed pharmacological investigations to be undertaken, especially the quantification and visualization of specific ligandÀ receptor complexes in intact cells. 7 The recent discovery that GPCRs can regulate signaling pathways that are independent of G proteins has led to a realization that different signal transduction pathways can be selectively stimulated by agonists acting at a common cell surface receptor. 8À11 GPCRs are not uniformly distributed at the cell surface but instead are organized within membrane compartments and microdomains, 12, 13 providing a mechanism by which intracellular signaling can be orchestrated in different areas of an individual cell and behave differently in specific cell types. 14 This new mechanistic information has focused attention on the need to develop fluorescent ligands to study the spatial and temporal aspects of ligandÀreceptor interactions. 15, 16 With their established clinical and therapeutic importance, 17 it is therefore not surprising that β-AR have been investigated within this area of pharmacological imaging.
To-date, however, only a handful of reports have been published detailing limited success in the synthesis of fluorescent β-AR ligands (Figure 1 ). The earliest studies detailed the use of fluorescent propranolol derivatives 9-aminoacridinylpropranolol (9-AAP) (1) 18À22 and dansyl-propanolol (DAPN) (2) 23 to investigate receptor mapping and clustering. Following this, synthesis of an NBDÀalprenolol derivative (3) was reported and utilized in further clustering studies. 24 However, it was later demonstrated that 3 and NBDÀpindolol (4) were in fact both nonselective and noncompetitive. 25, 26 Additionally, two reports also detailed that during their use of 1 and 2 they were unable to distinguish between the binding of these ligands to cellular receptors and autofluorescent granules, concluding that the fluorescent output from these ligands was therefore of too low an intensity to be detected by fluorescence microscopy. 27, 28 A decade later, a significant advance was achieved through the synthesis of bordifluoropyrromethene-(BODIPY) (5) and fluorescein-labeled (6) β-AR ligands. 29 On the basis of the hydrophilic β-AR ligand 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one (CGP 12177), 30 it was demonstrated that the BODIPY conjugate (5) displayed similar binding characteristics when compared with the standard ligand. The fluorescein conjugate's (6) receptor-specific signal was not sufficiently strong enough for subsequent pharmacological measurement and has indeed since been demonstrated to suffer from significant photobleaching during fluorescence microscopy experiments. 31 A variant of CGP 12177 (BODIPY TMRÀCGP 12177) (7) has also been reported and shown to be a long-acting β2-AR partial agonist capable of labeling β2-AR in the plasma membrane of living cells. 32 More recently, the first description of a fluorescently labeled arterenol derivative (Alexa-NA) (8) and its use in fluorescence correlation spectroscopy (FCS) based studies to investigate β2-AR in living cells was published. 33 In addition, a europium-chelated fluorescent derivative of pindolol for use in time-resolved receptorÀligand binding assays has also been described, but its full structure was not revealed. 34 Within this rapidly evolving arena of pharmacological imaging, we have previously reported the synthesis of red-shifted BOD-IPY-labeled fluorescent adenosine receptor agonists 16, 35, 36, 38 and antagonists 37, 38 and demonstrated their utility in measuring the diffusion of receptor species within defined membrane microdomains using the technique of fluorescence correlation spectroscopy (FCS). 39 Avoiding the issues of autofluorescence, highlighted as being severely problematic with many of the derivatives discussed above, was one of our primary objectives in designing pharmacologically useful fluorescent ligands. Clearly, fluorescent ligands that emit light in the red region of the electromagnetic spectrum meet this requirement and, in addition, often possess excellent photophysical properties suited for techniques such as LSCM and FCS. With the previously described fluorescent β-AR ligands either not meeting these requirements for fluorescence microscopy or, as in the case of BODIPY TMRÀCGP 12177, no longer commercially available, we were keen to generate a new suite of red-shifted fluorescent β-AR ligands for use in LSCMand FCS-based experiments. Three families of fluorescent ligands based on propranolol, alprenolol, and pindolol were synthesized, 
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ARTICLE characterized, and pharmacologically assessed across the human forms of the β1-, β2-, and β3-ARs. Our choices of β-AR ligands were based primarily upon synthetic tractability, a desire to improve upon those ligands previously described, and to address three key questions surrounding ligand design: (i) Was the effect of linker length and composition similar to what we had observed for the corresponding adenosine ligands? 36 (ii) With structural extension of the pharmacophore to include both a linker and fluorophore, did the stereochemistry of the crucial carbinol center exert the same effect on affinity as that previously established for β-AR antagonists? (iii) Could the best fluorophoreÀlinker combination from the initial "propranolol" library be transposed onto alternative orthosteric head-groups (alprenolol and pindolol) without deleterious effects on pharmacology.
' RESULTS AND DISCUSSION Synthesis. We initially embarked upon the synthesis of a focused library of fluorophore-conjugated single enantiomer and racemic propranolol derivatives (Scheme 1). Commercially available 1-napthol (9) was therefore alkylated with either (2S)-glycidyl-3-nitrobenzenesulfonate or racemic epichlorohydrin as previously described to afford epoxides 10a and 10b, respectively. 40 Nucleophilic ring-opening of the epoxides was effected using a range of appropriately mono-Cbz-protected diamines (11aÀc and 15) to afford carbinolamines 12aÀf, 16a, and 16b. Subsequent hydrogenolysis of the Cbz protecting groups afforded the linker-modified congeners 13aÀf, 17a, and 17b primed for chemoselective acylation of the terminal primary amine with commercially available 6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)aminohexanoic acid succinimidyl ester (BODIPY 630/650-X, SE; Invitrogen). Aminolysis of the fluorophore active ester proceeded smoothly and the fluorescently labeled ligands 14aÀf, 18a, and 18b were isolated and purified using preparative thin-layer chromatography (PTLC); their purity was confirmed using RP-HPLC with photodiode array detection between 190 and 800 nm. Evaluation of these ligands highlighted that linker length exerted minimal overall influence on receptor affinity, and for expeditious reasons, the alprenolol and pindolol conjugates were therefore synthesized using only the ethylamino (short hydrocarbon) and ethoxyethoxyethylamino (long polyether) linker variants.
The S-enantiomer (23a and 26a) and racemic (23b and 26b) alprenolol-BODIPY fluorescent ligands were therefore synthesized using an identical strategy to that of the propranolol derivatives, but starting from commercially available 2-allylphenol and replacing the Cbz-protected diamines with their tertbutoxycarbonyl (Boc) equivalents (Scheme 2).
Finally, having also established with these initial two series that the (S)-enantiomer exerted the expected shift in log K D values, we generated the final pindolol-based molecules in their inexpensive racemic form. Therefore, (()-4-[(oxiran-2-yloxy)methyl]-1H-indole (28) was ring-opened using either 11a or 15 to afford the Cbz-protected carbinolamine congeners 29 and 32, respectively. Cbz hydrogenolysis and acylation of the relinquished amines with BODIPY 630/650-X, SE ultimately Pharmacology. 3 H-CGP 12177 Whole Cell Binding Studies. Measurement of 3 H-CGP 12177 binding to CHO cells expressing the human β1-, β2-, or β3-AR indicated that all compounds displayed the highest affinity for the human β2-AR ( Table 1) . The lowest affinity compounds were the pindolol derivatives 31 and 34. Increasing the linker chain length from C-2 to C-8 for the propranolol series caused a modest increase in affinity from C-2 (14a, 14d) to C4 (14b, 14e) but then a 10-fold reduction in affinity with a further doubling in linker chain length to C-8 (14c, 14f) ( Table 1 ). It was notable that the C-8 derivative 14f did not completely displace the specific binding of 3 H-CGP 12177 to the human β1-AR (maximal displacement of specific binding =65.9 ( 2.0%; Table 1 ; Figure 2a ).
This was seen to a lesser extent with the pure S-enantiomer 14c (85.3 ( 2.4% maximal inhibition; Figure 2a ), suggesting that the R-enantiomer may be contributing an allosteric influence on the orthosteric binding site. It was also striking that 14f did not produce an effect to the same degree in cells expressing the human β2-AR ( Figure 2b ).
Substitution of a polyethylene glycol linker in place of the C-8 hydrocarbon chain in 14c provided the highest affinity ligand 18a at the human β2-AR (log K D = À9.21; Table 1 ). This compound also had lower but respectable affinities at the human β1-AR (log K D = À7.76) and β3-AR (log K D = À7.09). The equivalent molecule from the alprenolol series 26a also displayed high affinity for the β1-AR (log K D = À7.65) and β2-AR (log K D = À9.03; Figure 3 ). However, 34, from the pindolol series, was an order of magnitude less potent compared to its parent molecule ( Table 1) .
It was notable that the addition of fluorophore and linker did not markedly change the affinities of the parent compounds for the β3-AR. In the case of both propranolol and alprenolol, the C-2 linker derivatives had the highest affinity for this particular receptor ( Table 1) .
Functional Reporter Gene Studies. To gain some insight into the ability of these ligands to antagonize agonist-stimulated responses at each receptor, we evaluated their ability to attenuate functional activity in the CHO cells as they also expressed the target receptor and a six cyclic AMP response element (6 Â CRE) reporter gene driving the expression of a human-secreted placental alkaline phosphatase reporter gene. 41, 42 Agonist responses were elicited by cimaterol (β1, site 1), salbutamol (β2), and fenoterol (β3). For the β1-AR site 2, agonist responses were elicited by CGP 12177. All of the propranolol derivatives were potent competitive antagonists of this response, with 18a once again displaying the highest affinity (Table 2; Figure 4 ).
The alprenolol and pindolol series showed partial agonist activity ( Figure 5 ; Table 3 ) on all three β-AR subtypes. These 
ARTICLE observations are consistent with the agonist nature of the parent compounds on all three receptors (Table 3 ). 41À43 Interestingly, the presence of the fluorophore/linker combination reduced the agonist efficacy of both alprenolol and pindolol at the β2-AR, particularly, but had a much smaller influence on agonist efficacy at the other two β-ARs (Table 3 ). This suggests that the presence of the BODIPY unit or the associated linker chemistry can modify agonist efficacy in a receptor subtype specific manner and implies that the design of ligands with receptor selectivity based on efficacy rather than ligand-binding affinity may be possible. 44 As a consequence of the partial agonist activity, the log K D values for alprenolol, pindolol, and their derivatives shown in Table 2 were calculated according to the partial agonist method of Stephenson. 45 Previous work on the human β1-AR has shown that this receptor can exist in two conformations that can both elicit functional responses. The first site has high affinity for the majority of β-antagonists and is the site at which isoprenaline and other catecholamines elicit their agonist responses. The second site can be activated by high concentrations of CGP 12177 and is generally relatively resistant to antagonism by standard β-blockers. 46 In order to evaluate the ability of fluorescent ligands to antagonize functional responses via these two sites, we used cimaterol as an agonist of site 1 and CGP 12177 as an agonist of site 2. 47,10 All fluorescent ligands were effective antagonists of site 1 of the β1-AR with the PEG-8 derivatives 18a (Table 2) , 26a, and 34 being the most potent. The inhibition of agonist responses to CGP 12177 provided the first indication of the affinity of these fluorescent ligands for site 2 of the β1-AR. All compounds tested had a lower affinity for site 2 than for site 1 ( Table 2 ). However, it was striking that linker length and the presence of the fluorophore did not markedly change the affinity of the parent ligand for site 2 ( Table 2 ). As noted from binding studies, this was also true of the β3-AR, and the functional studies confirmed the higher affinity of C2-linked propranolol and alprenolol derivatives for this receptor ( Table 2) .
Confocal Imaging. An essential requirement of a fluorescent ligand for any GPCR is that its binding to cell surface receptors can be visualized and that this binding displays the pharmacology of the target receptor. We have previously shown from our work on adenosine A1 and A3 receptors that the BODIPY 630/650 fluorophore is heavily quenched in aqueous environments but markedly increases its quantum yield when bound to cell surface receptors because of its location in a more lipid environment. 38 This property has proved highly beneficial in studying ligandbinding kinetics at the single cell level. 15 Figure 6 shows the binding of 3 nM 18a to CHO cells expressing the β2-AR. Bright labeling of cell surface β2-AR can be detected even in the continued presence of 18a.
Quenching of the ligand present in the extracellular fluid is evident from the lack of fluorescence between the individual cells. Cell surface binding of 18a can be markedly inhibited by increasing concentrations (1À100 nM) of the β2-selective antagonist ICI 118551, consistent with its high affinity for the β2-AR. In contrast, the selective β1-AR antagonist 1- 48 only began to displace at concentrations above 10 μM, which is consistent with its low affinity for this receptor. 49 Finally, 3nM 18a produced only a low level of binding to the cell surface of control CHO cells not expressing the β2-AR ( Figure 6 ). This low level of binding was entirely consistent with the nonspecific binding observed in receptor-expressing cells incubated with 100 nM ICI 118551 ( Figure 6 ).
' CONCLUSIONS
A key feature of the current state of research into GPCRs is a growing awareness of the need to investigate their cellular location and involvement in proteinÀprotein interactions. This requires the development of methodologies to investigate the allosteric regulation of the ligandÀreceptor binding by small molecules or associated signaling proteins. We have shown previously that fluorescent ligands can be used to provide insights into the membrane organization of GPCRs using fluorescence correlation spectroscopy 37, 16 and also to reveal novel allosteric interactions using kinetic analysis of ligand association and dissociation in single living cells. 15,50 A key prerequisite for these 
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ARTICLE approaches is the design and synthesis of novel fluorescent ligands with the correct pharmacological and biophysical properties. In the present study, we have designed, synthesized, and characterized 14 new red-emitting fluorescent ligands (14aÀf, 18a,b, 23a,b, 26a,b, 31, and 34) for the human β-AR. Using alkyl-or polyether-based linker extension from the nitrogen atom of the conserved aryloxypropanolamine portion of propranolol, alprenolol, and pindolol generated a range of fully deprotected congeners, functionally equipped to undergo a high yielding chemoselective acylation with the commercially available fluorochrome BODIPY 630/650-X, SE (Molecular Probes). No protecting group manipulations were required following fluorophore attachment. This new range of fluorescent β-blockers displayed high affinity for the β2-AR, with some (18a and 26a) also possessing moderate affinity for the β1-AR. An evaluation of the pharmacology of the new fluorescent derivatives was undertaken. Compound 18a, in particular, displayed a log K D of À9.53 as an antagonist of functional responses mediated by the human β2-AR and a log K D of À8.46 as an antagonist of the high-affinity catecholamine site of the β1-AR.
Critically, we were further able to utilize these molecules to visualize ligandÀreceptor interactions using confocal microscopy. Confirmation of selective fluorescent labeling of, for example, the human β2-AR in single living cells was achieved by incubating CHO-β2 cells expressing the human β2-AR with a 3 nM concentration of 18a. This resulted in clear labeling of the cell membrane, with the receptor specific proportion of this binding blocked by preincubation with the nonfluorescent β2-selective antagonist ICI 118551. This fluorescent propranolol derivative should therefore be invaluable in future mechanistic studies aimed at unraveling the intricacies of cell signaling via this prototypical GPCR. Melting points were recorded on a Gallenkamp 3A 3790 apparatus and are uncorrected. FT-infrared spectra were recorded as thin films or KBr discs in the range of 4000À600 cm À1 using an Avatar 360 Nicolet FT-IR spectrophotometer. Optical rotation was measured on a Bellingham-Stanley ADP220 polarimeter. Mass spectra and HRMS TOF-ES mass spectra were recorded on a Waters 2795 Separation Module/ Micromass LCT platform. Proton nuclear magnetic resonance spectra were recorded on a Bruker-AV 400 (400 MHz) spectrometer. Carbon nuclear magnetic resonance spectra were recorded at 100.6 MHz. Unless otherwise stated, spectra were recorded in CDCl 3 . Chemical shifts (δ) are recorded in ppm with reference to the chemical shift of the deuterated solvent/an internal tetramethylsilane standard. Coupling constants (J) are recorded in hertz and the signal multiplicities described by s, singlet; d, doublet; t, triplet; q, quartet; br, broad; m, multiplet; dd, doublet of doublets. Spectra were assigned using appropriate COSY, DEPT, and HMQC sequences. Analytical reverse-phase high-performance liquid chromatography (RP-HPLC) was performed on a Waters Millennium 995 LC system using columns, gradients, and flow rates as described. The eluent was monitored using photodiode array detection. Mobile phases were solvent A, water; solvent B, acetonitrile (both containing 0.06% v/v trifluoroacetic acid) degassed by helium bubble and sonication, respectively. The purities of all compounds tested in biological systems were therefore assessed as being ∼95%. Monoprotected diamines [benzyl 2-aminoethylcarbamate, tert-butyl 2-aminoethylcarbamate, tert-butyl 2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate] were purchased (Sigma-Aldrich) or were synthesized [benzyl 4-aminobutylcarbamate, benzyl 8-aminooctylcarbamate, benzyl 2-(2-(2-aminoethoxy)ethoxy)ethylcarbamate] as previously described. 36, 51 (S)-2-((Naphthalen-1-yloxy)methyl)oxirane (10a). A portion of 60% NaH in mineral oil (610 mg, equivalent to 366 mg of NaH, 15.26 mmol, 1.1 equiv) was dispersed in anhydrous DMF (2 mL) under an atmosphere of nitrogen at room temperature. To this vigorously stirred suspension was added a solution of 1-naphthol (2.00 g, 13.87 mmol) in anhydrous DMF (8 mL). The resulting pale green suspension was stirred at room temperature for 30 min. A solution of (S)-glycidyl nosylate (3.632 g, 14.01 mmol, 1.01 equiv) in anhydrous DMF (5 mL) was added dropwise to the reaction mixture. Once addition was complete, the mixture was heated at 60°C overnight before cooling and quenching with aqueous saturated NH 4 Cl. The mixture was concentrated to dryness under reduced pressure and the resulting residue dispersed in water (100 mL). The aqueous slurry was extracted with Et 2 O (3 Â 50 mL), and the combined organic extracts were washed with aqueous 1 M NaOH (50 mL) and brine (50 mL). After drying over anhydrous MgSO 4 , the organic extracts were concentrated under reduced pressure. The crude product was further purified by flash column chromatography (eluent EtOAc/ petroleum ether 40À60 0:100 to 30:70 over 10 column volumes) to afford a colorless oil (2.44 g, 88%). (S)-2-((2-Allylphenoxy)methyl)oxirane (20a). A portion of 60% NaH in mineral oil (656 mg, equivalent to 394 mg NaH, 16.40 mmol, 1.1 equiv) was dispersed in anhydrous DMF (2 mL) under an atmosphere of nitrogen at room temperature. To this vigorously stirred suspension was added a solution of 2-allylphenol (2.00 g, 14.91 mmol) in anhydrous DMF (8 mL). The resulting pale green suspension was stirred at room temperature for 30 min. A solution of (S)-glycidyl nosylate (3.903 g, 15.05 mmol, 1.01 equiv) in anhydrous DMF (5 mL) was added dropwise to the reaction mixture. Once addition was complete, the mixture was heated at 60°C overnight before cooling and quenching with aqueous saturated NH 4 Cl. The mixture was concentrated to dryness under reduced pressure and the resulting residue dispersed in water (100 mL). The aqueous slurry was extracted with Et 2 O (3 Â 50 mL), and the combined organic extracts were washed with aqueous 1 M NaOH (50 mL) and brine (50 mL). After drying over anhydrous MgSO 4 , the organic extracts were concentrated under reduced pressure. The crude product was further purified by flash column chromatography (eluent EtOAc/petroleum-ether 40À60 0:100 to 30:70 over 10 column volumes) to afford a clear yellow oil (2.97 g, quantitative). (()-Benzyl 4-(2-Hydroxy-3-(naphthalen-1-yloxy)propylamino)butylcarbamate (12e). A solution of 2-(napthalen-1-yloxymethyl)oxirane (10b) (0.20 g, 1 mmol) and benzyl 4-aminobutylcarbamate (11b) (0.56 g, 2.5 mmol) in DMF/H 2 O 9:1 (5 mL) was heated at 85°C for 16 h. The solvent was evaporated under reduced pressure and the crude material was purified by flash column chromatography on silica employing a gradient from 0 to 10% MeOH in CH 2 Cl 2 as eluent to afford the title compound as a yellow solid (0.245 g, 58%). Mp 90À91°C. 1 Journal of Medicinal Chemistry ARTICLE 10% Pd/C (1:1 w/w with protected amine). The solvent was briefly degassed and hydrogen was added via balloon; the mixture was then stirred at room temperature for 1 h. The reaction mixture was filtered through Celite and the pad was washed with MeOH (Â2). The solvent was evaporated under reduced pressure to afford the deprotected amine, which was used without further purification.
(()-1-(4-Aminobutylamino)-3-(napthalenyl-1-yloxy)propan-2-ol (13e). The compound was prepared via method A to yield a colorless oil (quant.). 1 13 where E max is the maximum response, [A] is the agonist concentration, and EC 50 is the concentration of agonist that produces 50% of the maximal response The affinities of antagonist drugs were calculated (K D values) from the shift of the agonist concentration responses in the presence of a fixed concentration of antagonist using eq 4:
where DR (dose ratio) is the ratio of the agonist concentration required to stimulate an identical response in the presence and absence of a fixed concentration of antagonist, [B] . Where clear partial agonism was observed (e.g., Figure 5 ), the affinity was calculated according to the method 45 of Stephenson using eq 5:
where [P] in the concentration of the partial agonist, [A 1 ] in the concentration of the agonist at the point where the partial agonist alone agonist causes the same response, [A 2 ] is the concentration of agonist causing a given response above that achieved by the partial agonist, and [A 3 ] the concentration of the agonist, in the presence partial agonist, causing the same stimulation as [A 2 ].
' ASSOCIATED CONTENT 
